FDA-Regulated Pharmaceutical Marketing: A Practical Overview

If you market prescription medicines in the United States, the Food and Drug Administration (FDA) sets the ground rules. Unlike the UK's ABPI Code — which is a self-regulatory code — US promotion is enforced through federal regulations, most commonly 21 CFR Part 202. This guide covers the essentials your MLR team works to every day.

The Legal Basis

Prescription drug promotion in the US is regulated under the Federal Food, Drug, and Cosmetic Act and its implementing regulations. The key requirements for promotional materials are found in 21 CFR 202.1, which sets out what prescription drug advertisements must contain.

True Statements and Fair Balance

Promotional materials must be truthful, non-misleading, and fairly balanced. In practice, this means the benefits of a product cannot be presented without the risks in a comparable way.

The FDA expects that promotional pieces:

• Present the efficacy claims and the risk information with comparable prominence.
• Not omit material facts that would make the claims misleading.
• Include the established name and the quantitative ingredient information where required.
• Make the information consistent with the approved labelling.

HCP vs Direct-to-Consumer Promotion

The US is one of the few countries where direct-to-consumer (DTC) promotion of prescription drugs is permitted. This creates two distinct audiences with different rules:

• HCP promotion targets healthcare professionals through medical journals, sales materials, and professional channels.
• DTC promotion reaches consumers through broadcast, print, and digital advertising.
• Both must be truthful and fairly balanced, but the format and detail differ.

The Major Statement and Brief Summary

For broadcast DTC advertisements, the FDA requires a 'major statement' of the product's most important risks in the audio or visual portions of the ad. Print ads use a 'brief summary' of prescribing information.

These are structural requirements, not optional extras — an ad that omits the major statement is non-compliant regardless of the content's accuracy.

Adverse Event Reporting

Pharmacovigilance obligations run alongside marketing. Companies must report adverse events, and promotional materials must make it clear how healthcare professionals and consumers can report them.

How RegScribe Helps

RegScribe supports both ABPI (UK) and FDA (US) drafting. When you select the FDA framework, it generates first-draft copy with fair-balance framing, safety disclaimers, and a reference block — a regulation-aware starting point your MLR team can refine, not rebuild.